CA2188872A1 - Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use - Google Patents
Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of useInfo
- Publication number
- CA2188872A1 CA2188872A1 CA002188872A CA2188872A CA2188872A1 CA 2188872 A1 CA2188872 A1 CA 2188872A1 CA 002188872 A CA002188872 A CA 002188872A CA 2188872 A CA2188872 A CA 2188872A CA 2188872 A1 CA2188872 A1 CA 2188872A1
- Authority
- CA
- Canada
- Prior art keywords
- physiologically acceptable
- acceptable emulsions
- methods
- emulsions containing
- magnetic resonance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000839 emulsion Substances 0.000 title abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title abstract 2
- -1 perfluorocarbon ether hydrides Chemical class 0.000 title abstract 2
- 238000005481 NMR spectroscopy Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 238000012984 biological imaging Methods 0.000 abstract 1
- 239000003633 blood substitute Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000002591 computed tomography Methods 0.000 abstract 1
- 239000002872 contrast media Substances 0.000 abstract 1
- 229940039231 contrast media Drugs 0.000 abstract 1
- 238000007887 coronary angioplasty Methods 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000002604 ultrasonography Methods 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D1/00—Fire-extinguishing compositions; Use of chemical substances in extinguishing fires
- A62D1/0028—Liquid extinguishing substances
- A62D1/0035—Aqueous solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D12/00—Displacing liquid, e.g. from wet solids or from dispersions of liquids or from solids in liquids, by means of another liquid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
- B23K—SOLDERING OR UNSOLDERING; WELDING; CLADDING OR PLATING BY SOLDERING OR WELDING; CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING; WORKING BY LASER BEAM
- B23K35/00—Rods, electrodes, materials, or media, for use in soldering, welding, or cutting
- B23K35/22—Rods, electrodes, materials, or media, for use in soldering, welding, or cutting characterised by the composition or nature of the material
- B23K35/38—Selection of media, e.g. special atmospheres for surrounding the working area
- B23K35/386—Selection of media, e.g. special atmospheres for surrounding the working area for condensation soldering
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/24—Preparation of ethers by reactions not forming ether-oxygen bonds by elimination of halogens, e.g. elimination of HCl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/48—Preparation of compounds having groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/04—Saturated ethers
- C07C43/12—Saturated ethers containing halogen
- C07C43/123—Saturated ethers containing halogen both carbon chains are substituted by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/04—Saturated ethers
- C07C43/12—Saturated ethers containing halogen
- C07C43/126—Saturated ethers containing halogen having more than one ether bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C43/192—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/313—Compounds having groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
- C07C59/135—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2203/00—Foams characterized by the expanding agent
- C08J2203/14—Saturated hydrocarbons, e.g. butane; Unspecified hydrocarbons
- C08J2203/146—Saturated hydrocarbons containing oxygen and halogen atoms, e.g. F3C-O-CH2-CH3
Abstract
This invention relates to physiologically acceptable emulsions of perfluorocarbon ether hydrides having 8 to 12 carbon atoms. These novel emulsions have various medical applications. They are especially useful medically as contrast media for various biological imaging modalities such as nuclear magnetic resonance, 19F-magnetic resonance imaging, ultrasound, x-ray, and computed tomography, as oxygen transport agents or "artificial bloods" in the treatment of heart attack, stroke, and other vascular obstructions, as adjuvants to coronary angioplasty and in cancer radiation treatment and chemotherapy.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US246,962 | 1994-05-20 | ||
US08/246,962 US5476974A (en) | 1994-05-20 | 1994-05-20 | Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application |
US437,299 | 1995-05-17 | ||
US08/437,299 US5502094A (en) | 1994-05-20 | 1995-05-17 | Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use |
PCT/US1995/006327 WO1995031965A1 (en) | 1994-05-20 | 1995-05-19 | Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2188872A1 true CA2188872A1 (en) | 1995-11-30 |
CA2188872C CA2188872C (en) | 2008-09-16 |
Family
ID=26938352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002188872A Expired - Fee Related CA2188872C (en) | 1994-05-20 | 1995-05-19 | Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use |
Country Status (8)
Country | Link |
---|---|
US (2) | US5502094A (en) |
EP (1) | EP0759742B1 (en) |
JP (1) | JPH10500689A (en) |
AU (1) | AU2596695A (en) |
CA (1) | CA2188872C (en) |
DE (1) | DE69505657T2 (en) |
RU (1) | RU2159610C2 (en) |
WO (1) | WO1995031965A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2795915C1 (en) * | 2022-07-12 | 2023-05-15 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | 1,2-BIS(PERFLUORO-tert-BUTOXY)ETHANE AS A CONTRAST FOR 19F NUCLEUS MAGNETIC RESONANCE IMAGING |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US20020150539A1 (en) * | 1989-12-22 | 2002-10-17 | Unger Evan C. | Ultrasound imaging and treatment |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US5656211A (en) | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US5628930A (en) * | 1992-10-27 | 1997-05-13 | Alliance Pharmaceutical Corp. | Stabilization of fluorocarbon emulsions |
US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
US5736121A (en) | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US5804162A (en) * | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
IT1283203B1 (en) * | 1996-03-07 | 1998-04-16 | Ausimont Spa | FIRE EXTINGUISHING COMPOSITIONS |
JP2001507207A (en) | 1996-05-01 | 2001-06-05 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | Methods for delivering compounds to cells |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
CA2263568C (en) | 1996-09-11 | 2008-12-02 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a contrast agent and a renal vasodilator |
WO1998016617A1 (en) * | 1996-10-17 | 1998-04-23 | Advanced Chemical Design, Inc. | Environmentally safe bromopentane composition for cleaning metallic, electrical and plastic materials |
US6331286B1 (en) | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
AU5161298A (en) * | 1996-11-25 | 1998-06-22 | Imarx Pharmaceutical Corp. | Perfluorinated-ether compositions as diagnostic contrast agents |
US6020298A (en) * | 1997-03-05 | 2000-02-01 | Ausimont S.P.A. | Solvent cleaning agents including additives of the formula Rf -CFX-L containing perfluoroalkylenic units |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6537246B1 (en) * | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US6221261B1 (en) | 1997-08-13 | 2001-04-24 | Edward E. Boss | Process for treating sewage using hydro fluoro ether polymers |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US8974363B2 (en) | 1997-12-11 | 2015-03-10 | Provectus Pharmatech, Inc. | Topical medicaments and methods for photodynamic treatment of disease |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
US8557298B2 (en) | 1998-08-06 | 2013-10-15 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
US6070465A (en) * | 1998-08-24 | 2000-06-06 | Dresser Industries | Free water measurement apparatus and method thereof |
US20040047804A1 (en) * | 1998-10-29 | 2004-03-11 | The General Hospital Corporation, A Massachusetts Corporation | Enhanced radiation therapy |
US20010039952A1 (en) | 1998-11-10 | 2001-11-15 | Walter A. Hacker, Ph. D | Ultrasound enhanced chemotherapy |
US6127430A (en) * | 1998-12-16 | 2000-10-03 | 3M Innovative Properties Company | Microemulsions containing water and hydrofluroethers |
US6159917A (en) * | 1998-12-16 | 2000-12-12 | 3M Innovative Properties Company | Dry cleaning compositions containing hydrofluoroether |
US8470296B2 (en) * | 1998-12-21 | 2013-06-25 | Provectus Pharmatech, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
US20020001567A1 (en) * | 1998-12-21 | 2002-01-03 | Photogen, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
US7384623B1 (en) | 1998-12-21 | 2008-06-10 | Provectus Pharmatech, Inc. | High energy phototherapeutic agents |
CA2474134C (en) * | 2002-01-15 | 2015-11-17 | Board Of Regents, The University Of Texas System | Methods and compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures |
EP1365068B1 (en) * | 2002-05-10 | 2008-05-07 | The Procter & Gamble Company | Embossed tissue having loosened surface fibers and method for its production |
US20090117207A1 (en) * | 2005-11-29 | 2009-05-07 | Zoltani Csaba K | Methods and compositions for treatment of poison-caused pathology |
DE102006049821A1 (en) * | 2006-10-18 | 2008-04-24 | Bayer Schering Pharma Aktiengesellschaft | New, well tolerated metal chelates, for use as radiodiagnostic, radiotherapeutic or NMR and X-ray diagnostic agents, contain chelator and perfluorinated polyethylene glycol residues |
US8575403B2 (en) | 2010-05-07 | 2013-11-05 | Celanese International Corporation | Hydrolysis of ethyl acetate in ethanol separation process |
WO2011130304A2 (en) * | 2010-04-12 | 2011-10-20 | University Of South Florida | Materials and methods for reliable measurement of blood volume |
US9272970B2 (en) | 2010-07-09 | 2016-03-01 | Celanese International Corporation | Hydrogenolysis of ethyl acetate in alcohol separation processes |
WO2012148509A1 (en) | 2011-04-26 | 2012-11-01 | Celanese International Corporation | Process for producing ethanol using a stacked bed reactor |
US8710279B2 (en) | 2010-07-09 | 2014-04-29 | Celanese International Corporation | Hydrogenolysis of ethyl acetate in alcohol separation processes |
US8859827B2 (en) | 2011-11-18 | 2014-10-14 | Celanese International Corporation | Esterifying acetic acid to produce ester feed for hydrogenolysis |
US8664454B2 (en) | 2010-07-09 | 2014-03-04 | Celanese International Corporation | Process for production of ethanol using a mixed feed using copper containing catalyst |
US8927787B2 (en) | 2011-04-26 | 2015-01-06 | Celanese International Corporation | Process for controlling a reboiler during alcohol recovery and reduced ester formation |
US8754268B2 (en) | 2011-04-26 | 2014-06-17 | Celanese International Corporation | Process for removing water from alcohol mixtures |
US9073816B2 (en) | 2011-04-26 | 2015-07-07 | Celanese International Corporation | Reducing ethyl acetate concentration in recycle streams for ethanol production processes |
US8592635B2 (en) | 2011-04-26 | 2013-11-26 | Celanese International Corporation | Integrated ethanol production by extracting halides from acetic acid |
US8895786B2 (en) | 2011-08-03 | 2014-11-25 | Celanese International Corporation | Processes for increasing alcohol production |
US8748673B2 (en) | 2011-11-18 | 2014-06-10 | Celanese International Corporation | Process of recovery of ethanol from hydrogenolysis process |
US8829249B2 (en) | 2011-11-18 | 2014-09-09 | Celanese International Corporation | Integrated esterification and hydrogenolysis process for producing ethanol |
US9024089B2 (en) | 2011-11-18 | 2015-05-05 | Celanese International Corporation | Esterification process using extractive separation to produce feed for hydrogenolysis |
US8802901B2 (en) | 2011-11-18 | 2014-08-12 | Celanese International Corporation | Continuous ethyl acetate production and hydrogenolysis thereof |
US8829251B2 (en) | 2011-11-18 | 2014-09-09 | Celanese International Corporation | Liquid esterification method to produce ester feed for hydrogenolysis |
US8853468B2 (en) | 2011-11-18 | 2014-10-07 | Celanese International Corporation | Vapor esterification method to produce ester feed for hydrogenolysis |
US8927790B2 (en) | 2011-12-15 | 2015-01-06 | Celanese International Corporation | Multiple vapor feeds for hydrogenation process to produce alcohol |
US8975451B2 (en) | 2013-03-15 | 2015-03-10 | Celanese International Corporation | Single phase ester feed for hydrogenolysis |
ES2541226B2 (en) * | 2014-01-15 | 2016-02-12 | MONDRAGÓN GOI ESKOLA POLITEKNIKOA J. Mª. ARIZMENDIARRIETA, S.C | Blood phantom |
US11406722B2 (en) | 2017-03-16 | 2022-08-09 | The Board Of Regents Of The University Of Texas System | Nanodroplets with improved properties |
JP7002205B2 (en) * | 2017-03-23 | 2022-01-20 | 株式会社グッドマン | Pseudo-body fluid for simulator and medical simulator |
US10814268B2 (en) | 2018-03-29 | 2020-10-27 | Samuel L. Shepherd | Process for separating gases from gas mixtures using hydro fluoro ether |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3493581A (en) * | 1968-05-09 | 1970-02-03 | Basf Ag | Imidazolium salts |
US3911138B1 (en) * | 1973-02-26 | 1996-10-29 | Childrens Hosp Medical Center | Artificial blood and method for supporting oxygen transport in animals |
JPS5331209B2 (en) * | 1973-10-05 | 1978-09-01 | ||
GB1592349A (en) * | 1975-11-04 | 1981-07-08 | Silver Seiko | Programme reading apparatus for a knitting machine |
JPS5835485B2 (en) * | 1976-02-03 | 1983-08-03 | 株式会社ミドリ十字 | oxygen delivery infusion |
US4110474A (en) * | 1977-08-26 | 1978-08-29 | Suntech, Inc. | Tetramethylpentane blood substitutes |
US4187252A (en) * | 1977-08-26 | 1980-02-05 | Suntech, Inc. | Tetramethylpentane blood substitutes |
US4186253A (en) * | 1978-10-10 | 1980-01-29 | The Green Cross Corporation | Perfusate for preserving organ to be transplanted and preserving method |
US4252827A (en) * | 1979-05-23 | 1981-02-24 | The Green Cross Corporation | Oxygen-transferable fluorocarbon emulsion |
US4443480A (en) * | 1982-04-12 | 1984-04-17 | Children's Hospital Medical Center | Artificial blood and other gas transport agents |
US4423077A (en) * | 1982-07-27 | 1983-12-27 | The University Of Pennsylvania | Perfluorochemical emulsion artificial blood |
US4534978A (en) * | 1982-12-28 | 1985-08-13 | The Green Cross Corporation | Perfluorocycloamines |
CA1257828A (en) * | 1984-04-16 | 1989-07-25 | William Mccormick | Perfluoro compound dispersions containing reduced amounts of surfactant and process of preparation |
US4686024A (en) * | 1985-02-01 | 1987-08-11 | The Green Cross Corporation | Novel perfluoro chemicals and polyfluorinated compounds and process for production of the same |
US4868318A (en) * | 1985-02-01 | 1989-09-19 | The Green Cross Corporation | Perfluoro chemicals and polyfluorinated compounds |
US4865836A (en) * | 1986-01-14 | 1989-09-12 | Fluoromed Pharmaceutical, Inc. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
US4987154A (en) * | 1986-01-14 | 1991-01-22 | Alliance Pharmaceutical Corp. | Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use |
ES2054658T3 (en) * | 1986-01-24 | 1994-08-16 | Childrens Hosp Medical Center | METHOD FOR THE PREPARATION OF A PHYSIOLOGICALLY ACCEPTABLE EMULSION. |
US4866096A (en) * | 1987-03-20 | 1989-09-12 | Air Products And Chemicals, Inc. | Stable fluorochemical aqueous emulsions |
FR2620445B1 (en) * | 1987-09-16 | 1990-07-20 | Centre Nat Rech Scient | NOVEL FLUORINATED DERIVATIVES OF AMINO ACIDS, IN PARTICULAR FOR USE AS SURFACTANTS OR COTENSIOACTIVES AND BIOMEDICAL PREPARATIONS COMPRISING SUCH DERIVATIVES |
US5171755A (en) * | 1988-04-29 | 1992-12-15 | Hemagen/Pfc | Emulsions of highly fluorinated organic compounds |
FR2665705B1 (en) * | 1990-08-09 | 1993-07-30 | Atta | NOVEL AMPHIPHILIC FLUORINATED DERIVATIVES WITH A TELOMERIC STRUCTURE, PROCESS FOR THEIR PREPARATION AND THEIR USE IN PREPARATIONS FOR BIOMEDICAL USE. |
FR2679150A1 (en) * | 1991-07-17 | 1993-01-22 | Atta | PREPARATIONS CONSISTING OF A FLUOROCARBIDE OR HIGHLY FLUORINE COMPOUND AND A LIPOPHILIC-FLUOROPHILIC ORGANIC COMPOUND, AND THEIR USES. |
-
1995
- 1995-05-17 US US08/437,299 patent/US5502094A/en not_active Expired - Lifetime
- 1995-05-19 CA CA002188872A patent/CA2188872C/en not_active Expired - Fee Related
- 1995-05-19 EP EP95920545A patent/EP0759742B1/en not_active Expired - Lifetime
- 1995-05-19 WO PCT/US1995/006327 patent/WO1995031965A1/en active IP Right Grant
- 1995-05-19 JP JP7530433A patent/JPH10500689A/en not_active Withdrawn
- 1995-05-19 RU RU96122883/14A patent/RU2159610C2/en not_active IP Right Cessation
- 1995-05-19 AU AU25966/95A patent/AU2596695A/en not_active Abandoned
- 1995-05-19 DE DE69505657T patent/DE69505657T2/en not_active Expired - Fee Related
-
1996
- 1996-02-23 US US08/606,516 patent/US5567765A/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2795915C1 (en) * | 2022-07-12 | 2023-05-15 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | 1,2-BIS(PERFLUORO-tert-BUTOXY)ETHANE AS A CONTRAST FOR 19F NUCLEUS MAGNETIC RESONANCE IMAGING |
Also Published As
Publication number | Publication date |
---|---|
RU2159610C2 (en) | 2000-11-27 |
CA2188872C (en) | 2008-09-16 |
JPH10500689A (en) | 1998-01-20 |
WO1995031965A1 (en) | 1995-11-30 |
US5567765A (en) | 1996-10-22 |
EP0759742B1 (en) | 1998-10-28 |
DE69505657T2 (en) | 1999-07-15 |
DE69505657D1 (en) | 1998-12-03 |
AU2596695A (en) | 1995-12-18 |
US5502094A (en) | 1996-03-26 |
EP0759742A1 (en) | 1997-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2188872A1 (en) | Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods of use | |
EP0625068A4 (en) | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of making and using them. | |
Myers et al. | Pediatric low energy lithotripsy with the Lithostar | |
RU96122883A (en) | PHYSIOLOGICALLY COMPATIBLE EMULSIONS CONTAINING PERFORMATION AND HYDROGEN-HYDROGEN ETHERHYDRIDES, AND WAYS OF THEIR USE | |
MY109875A (en) | Novel formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight surfactants. | |
WO2005044365A3 (en) | Therapy via targeted delivery of nanoscale particles | |
Donnan | Investigation of patients with stroke and transient ischaemic attacks. | |
Schajowicz et al. | Intracortical haemangioma simulating osteoid osteoma | |
Khouri et al. | Pulmonary interstitial changes following bone marrow transplantation: A complex, multifactor disorder | |
Young et al. | Perfluoroctylbromide contrast enhancement of malignant neoplasms: preliminary observations | |
Men et al. | Intraaortic growth of hydatid cysts causing occlusion of the aorta and of both iliac arteries: case report | |
ITMI912889A1 (en) | PROCEDURE AND EQUIPMENT FOR THE UNIQUE COMBINATION OF RADIOGRAPHIC, ECOGRAPHIC, TOMOGRAPHIC, ANGIOGRAPHIC, MAGNETIC-NUCLEAR RESONANCE DOCUMENTS AND, IN GENERAL, OF ALL THE DOCUMENTS THAT ORIGINATE FROM THE DIAGNOSTIC PROCEDURES THAT THEY PRODUCE | |
Harrington | Historical Timeline | |
Elliott et al. | Significance of the caudal left-anterior-oblique view in analyzing the left main coronary artery and its major branches. | |
Kevles | Body imaging. | |
Jeremic | Second primary cancers occurring in patients with early stage non-small-cell lung cancer treated with radiation therapy alone | |
Uematsu et al. | Linear accelerator-based multifunctional treatment unit for stereotactic radiation therapy for extracranial tumors. | |
Hykes | Determination of patient radiation doses associated with cardiac catheterization procedures using direct measurements and Monte Carlo methods. | |
Isherwood | Diagnostic radiology | |
Ratcliffe | Effect of contrast agents on the lung | |
Das et al. | Efficacy of belly board device with CT-simulation in reducing small bowel volume within pelvic irradiation fields | |
Haq et al. | A complication of catheterization of the left internal jugular vein. | |
Yu | Evaluation of selenium-75 BISTAES as a potential articular cartilage imaging agent. | |
NOTTINGHAM | Nitrogen Mustard Hydrochloride-Boots | |
Archer-Hall | Ultrasonics international: Graz, Austria. 15–18 May, 1979 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |